#United States #Seattle #Atossa Therapeutics #Kathy Theall #Adebola Giwa

Atossa Therapeutics Strengthens Leadership in Biopharma

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Seattle, has announced significant additions to its clinical leadership team. The hiring of Dr. Kathy Puyana Theall and Dr. Adebola Giwa marks a strategic move aimed at advancing the company's pipeline of innovative therapies in oncology and rare diseases.

Enhancing Clinical Development with New Leadership

Dr. Theall joins Atossa as Medical Director - Breast Oncology. With over 24 years of experience in academia and the biopharmaceutical realm, she brings a wealth of expertise in the field of breast cancer drug development. Previously, she served as Vice President of Clinical Development at Stemline-Menarini, where she was pivotal in leading the clinical strategy leading to the FDA approval of ORSERDU™ in 2023. Her extensive background includes senior roles at Pfizer, where she contributed to the development of IBRANCE®, a breakthrough treatment for breast cancer.

"Atossa is at an important stage of growth," said Dr. Theall. "The company’s commitment to advancing innovative therapies in breast cancer aligns with my experience and passion. I am eager to contribute to the company’s continued development."

Dr. Giwa, appointed as Medical Director - Rare Diseases, is a board-certified pediatrician with specialized training in pediatric endocrinology from Johns Hopkins University. With more than 15 years of experience in clinical development, he has been involved in various clinical projects across multiple therapeutic areas, including endocrinology and nephrology. His most recent position was Senior Medical Director at Maze Therapeutics, where he led efforts on a genetic chronic kidney disease program.

"I am excited to join Atossa and play a role in advancing its clinical programs," Dr. Giwa stated. "The chance to help develop innovative therapies for patients with significant unmet medical needs is incredibly meaningful. I look forward to working with the team to elevate the company’s clinical capability and deliver high-quality data."

A Focus on Innovative Therapies

Atossa Therapeutics is known for its commitment to developing radical treatments aimed at cancers and rare diseases. The additions of Dr. Theall and Dr. Giwa are anticipated to significantly bolster the company's initiative to handle clinical programs centered around the company's lead product candidate, (Z)-Endoxifen. This innovative treatment is currently advancing through several clinical trials, with a focus on delivering effective solutions to patients suffering from critical conditions, including breast cancer and rare endocrine disorders.

Dr. Steven Quay, the CEO of Atossa, expressed enthusiasm about the new leadership appointments, emphasizing their potential to streamline the company's clinical strategies and enhance overall operational efficiency. "Kathy’s proven track record in late-stage oncology development combined with Adebola’s expertise in rare diseases will augment our capabilities to further our clinical goals and regulatory achievements," Dr. Quay remarked.

Commitment to Patients and Innovation

As Atossa Theraputics looks ahead, the company is positioned to tackle the pharmaceutical demands of oncology and rare diseases with renewed vigor. The synergistic expertise of its leadership is expected to advance key clinical milestones while adhering to rigorous safety and regulatory protocols. The goal remains clear: to deliver meaningful health outcomes and improved patient quality of life through innovative treatments.

In summary, the strategic appointment of Dr. Theall and Dr. Giwa highlights Atossa Therapeutics' commitment to not only enhancing its clinical leadership but also ensuring that it remains at the forefront of biopharmaceutical innovation. With a robust pipeline and a dedicated team, Atossa is poised for a dynamic journey in the pharmaceutical landscape.

For more information on Atossa Therapeutics and their pioneering work, visit Atossa's website.